COMMENTARY

Sulfonylureas: Just Stop

Charles P. Vega, MD

Disclosures

August 13, 2018

Hello. I'm Dr Charles Vega, and I am a clinical professor of family medicine at the University of California at Irvine. Welcome to Medscape Morning Report, our 1-minute news story for primary care.

Switching therapy from metformin to a sulfonylurea increases the risk for adverse outcomes in patients with type 2 diabetes, according to a new study of 77,000 patients in the UK Clinical Practice Research Datalink.

Patients taking sulfonylureas as second-line therapy—replacing rather than adding on to metformin—had increased risks for myocardial infarction, all-cause mortality, and severe hypoglycemia compared with those on metformin monotherapy. This was true even when metformin-only patients had suboptimal glycemic control.

This class of drugs is also associated with weight gain, which may contribute to arrhythmias and cardiac ischemia.

Current guidelines downplay the use of sulfonylureas, although they remain the most common second-line agents for type 2 diabetes despite their consistent association with higher cardiovascular risk and the availability of newer classes of medications.

An editorial[1] reminded us that continuing metformin alone and accepting higher A1c targets is preferable to switching to sulfonylureas for both macrovascular outcomes and hypoglycemia.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....